Tharimmune Secures $2.02 Million to Drive Development Programs

Tharimmune, Inc., a biotechnology company based in Bridgewater, New Jersey, announced a private placement deal, raising approximately $2.02 million. This agreement involves issuing 961,446 common shares and warrants for an additional 480,723 shares. Each share is priced at $2.10, with the warrants exercisable six months post-issuance at $2.031 per share, expiring in five and a half years.

The financing was spearheaded by Gravitas Capital and SDS Capital Group, with President Street Global as the exclusive placement agent. The net proceeds aim to drive clinical development, particularly the TH104 program, which targets chronic pruritus in primary biliary cholangitis, an autoimmune liver condition. Additionally, Tharimmune plans to address general working capital needs.

This funding underscores Tharimmune's commitment to innovation in immunology and inflammation therapeutics, advancing its diverse portfolio.